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Abstract
Acute Epstein-Barr virus (EBV) infection is the most common cause of Infectious Mononucleosis. Nearly all adult humans
harbor life-long, persistent EBV infection which can lead to development of cancers including Hodgkin Lymphoma, Burkitt
Lymphoma, nasopharyngeal carcinoma, gastric carcinoma, and lymphomas in immunosuppressed patients. BARF1 is an EBV
replication-associated, secreted protein that blocks Colony Stimulating Factor 1 (CSF-1) signaling, an innate immunity
pathway not targeted by any other virus species. To evaluate effects of BARF1 in acute and persistent infection, we mutated
the BARF1 homologue in the EBV-related herpesvirus, or lymphocryptovirus (LCV), naturally infecting rhesus macaques to
create a recombinant rhLCV incapable of blocking CSF-1 (DrhBARF1). Rhesus macaques orally challenged with DrhBARF1
had decreased viral load indicating that CSF-1 is important for acute virus infection. Surprisingly, DrhBARF1 was also
associated with dramatically lower virus setpoints during persistent infection. Normal acute viral load and normal viral
setpoints during persistent rhLCV infection could be restored by Simian/Human Immunodeficiency Virus-induced
immunosuppression prior to oral inoculation with DrhBARF1 or infection of immunocompetent animals with a recombinant
rhLCV where the rhBARF1 was repaired. These results indicate that BARF1 blockade of CSF-1 signaling is an important
immune evasion strategy for efficient acute EBV infection and a significant determinant for virus setpoint during persistent
EBV infection.
Citation: Ohashi M, Fogg MH, Orlova N, Quink C, Wang F (2012) An Epstein-Barr Virus Encoded Inhibitor of Colony Stimulating Factor-1 Signaling Is an Important
Determinant for Acute and Persistent EBV Infection. PLoS Pathog 8(12): e1003095. doi:10.1371/journal.ppat.1003095
Editor: Richard Longnecker, Northwestern University, United States of America
Received August 26, 2012; Accepted November 6, 2012; Published December 27, 2012
Copyright:  2012 Ohashi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by grants from the US Public Health Service (CA68051, DE18926). NEPRC services were also supported by a base grant (USPHS
P51RR00168). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: fwang@rics.bwh.harvard.edu
Introduction
Acute Epstein-Barr virus (EBV) infection is the most common
cause of Infectious Mononucleosis (IM). Once infected, EBV
persists in rare peripheral blood lymphocytes for the life of the host
[1]. Almost all humans are persistently EBV infected by adulthood,
and persistent EBV infection is almost always asymptomatic as long
as host immunity is intact. The number of virus-infected peripheral
blood lymphocytes, or virus setpoint, during persistent EBV
infection is stable over time [2]. However, in rare instances,
persistent infection leads to EBV-associated cancers such as
Hodgkin lymphoma, Burkitt lymphoma, nasopharyngeal carcino-
ma, gastric carcinoma, and B cell lymphomas in immunocompro-
mised people [1]. How virus setpoints are established, how cancer
develops from persistent EBV infection, and how virus setpoints
affect cancer development remain important unanswered questions.
EBV infection of peripheral blood lymphocytes in tissue culture
hasprovided detailed knowledgeforthe molecular events associated
with B cell growth transformation and virus replication [1]. Less
well understood are the dynamics of virus infection in humans
where EBV must penetrate the oral mucosa and amplify itself
during acute infection to gain access and establish persistent, latent
infection in the peripheral blood B cell compartment. The lack of
small animal models that can accurately reproduce the biology of
acute and persistent EBV infection has limited investigation of the
relationship between acute and persistent phasesof infection, as well
as identification of determinants for EBV infection outcomes.
Most non-human primates are infected with a herpesvirus that is
closely related to EBV and shares the biologic features of EBV
infection [3]. Infection of rhesus macaques with their EBV-related
herpesvirus, or lymphocryptovirus (LCV), provides a unique
opportunity for experimental studies of EBV pathogenesis [4]. The
rhLCVgenome is colinearlyhomologous to EBV [5], and the biology
of natural rhLCV infection is similar, if not identical, to EBV
infection of humans, eg oral transmission, acute viral load with
establishment of life-long persistent infection, and development of
virus-induced malignancies after immunosuppression [3]. Addition-
ally, the rhesus macaque cellular and humoral immune responses to
rhLCV infection closely mirror those of EBV-infected humans [6–9].
rhLCV-naive macaques can be experimentally infected by oral
inoculation, reproducing the natural route of transmission followed
by acute, persistent, as well as malignant LCV infection in association
with Simian Immunodeficiency Virus (SIV) infection that appears
indistinguishable from EBV infection of healthy and Human
Immunodeficiency Virus (HIV)-infected humans [4,10].
Experimental animal models are important for dissecting the
consequences of host-pathogen interactions, especially viral proteins
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least five proteins capable of modifying host immunity to EBV
infection. All five viral proteins are expressed during replicative, but not
latent, infection indicative of their importance for disruption of host
immune responses to viral replication. Three EBV proteins interfere
with Major Histocompatibility Complex (MHC) class I mediated
antigen presentation (BNLF2a, BILF1, and BGLF5; [11–13]), whereas
a fourth EBV protein, BCRF1, is an IL-10 homologue [14].
A fifth protein, BARF1, is secreted from infected cells and acts as
a soluble Colony Stimulating Factor-1 (CSF-1) receptor to block
CSF-1 mediated signaling, a pathway of innate immunity not
known to be targeted by other viruses [15]. CSF-1 is a cytokine
important for macrophage production, differentiation, and func-
tion,aswellasforbone and placentaldevelopment[16].BARF1isa
29 kda monomer which forms a novel hexameric ring to bind CSF-
1 [17] and interferes with CSF-1 signaling by multiple pathways
including sequestration of cytokine, interference with the receptor-
binding surface, and induction of a conformational change
preventing interaction with its native receptor [18]. BARF1
functionally blocks CSF-1-induced macrophage proliferation [15]
and interferon alpha production from mononuclear cells in vitro
[19]. Tissue culture studies with EBV and rhLCV mutants have
established that BARF1 is not essential for viral replication or B cell
immortalization [19,20]. The evolution of BARF1 homologues in
Old World non-human primate LCV [5], but non-essential role for
BARF1 in vitro indicates that BARF1 has an important role in
natural host infection. To better understand the role of BARF1 in
EBV infection, we mutated the BARF1 homologue in rhLCV to
study the effect on rhesus macaque infection.
Results
Oral Inoculation of rhLCV-Naı ¨ve Rhesus Macaques with a
Recombinant rhLCV Encoding a Defective rhBARF1: Acute
Infection
In order to test the importance of rhBARF1-mediated CSF-1
blockade in acute and persistent rhLCV infection, three rhLCV-
naı ¨ve rhesus macaques were orally inoculated with 10
6 transform-
ing units (TU) of a recombinant rhLCV (DrhBARF1) carrying a
truncated rhBARF1 previously shown to be incapable of blocking
CSF-1-mediated signaling [20]. Successful penetration of the oral
mucosa and invasion of the peripheral blood was evaluated by
reverse-transcriptase-mediated PCR (RT-PCR) amplification for
the rhLCV homologue of the small EBV-encoded RNAs
(rhEBER) in peripheral blood mononuclear cells (PBMC). EBER
are abundantly expressed in LCV-infected B cells, with approx-
imately 100,000 copies per cell [21], making rhEBER RT-PCR an
extremely sensitive assay for the detection of rare rhLCV-infected
cells in the peripheral blood [22].
PBMC were isolated from weekly peripheral blood samples and
distributed into multiple aliquots, with the number of cells per
aliquot dependent on total PBMC yield per blood draw (eg, 3, 5,
or 10610
6 PBMC/aliquot). RNA was extracted from individual
aliquots, and rhEBER and GAPDH RT-PCRs were performed.
Aliquots were scored as positive or negative after gel electropho-
resis and Southern blot hybridization of PCR products with
radiolabelled gene-specific oligonucleotide probes.
Representative RT-PCR assays after DrhBARF1 rhLCV oral
inoculation of a naı ¨ve rhesus macaque (Mm263-05) are shown in
Figure 1A. Single PBMC aliquots from weeks 0–6 tested negative
for rhEBER (Figure 1A, left panel), but repeat testing of a second
week 6 aliquot tested positive along with aliquots from week 7 and
8 (Figure 1A, middle panel). rhEBER RT-PCR testing of PBMC
aliquots from later time points were occasionally positive, eg week
30, 48, 54, and 70 as shown in Figure 1A (right panel).
The results of rhEBER RT-PCR assays for all Mm263-05
PBMC aliquots tested are summarized in Figure 1B (open
symbols=negative results, closed symbols=positive results). In
the acute phase (defined as weeks 0–16), 4 of 31 aliquots (12.9%)
were positive, and viral RNA was detectable between 6 to 8 weeks
post-oral inoculation, a time frame similar to the acute viral load
(weeks 3–10) reported previously by DNA PCR after experimental
inoculation with wild type (WT) rhLCV [10]. Oral inoculation of
two other rhLCV-naı ¨ve rhesus macaques with DrhBARF1 rhLCV
(Mm78-05 and Mm98-96 (1
st)) also resulted in intermittently
positive PBMC aliquots by rhEBER RT-PCR testing during the
acute phase (31.3% and 58.3% positive respectively).
These results were compared to inoculation with WT rhLCV by
using archived PBMC aliquots from rhesus macaques orally
inoculated with 10
6 TU of WT rhLCV (Mm141-97 and Mm144-
97 [10]). As shown in Figure 1C, rhEBER RT-PCR assays became
positive from 1–3 weeks after oral WT rhLCV inoculation, and
then stayed almost uniformly positive for months to years after oral
inoculation. Thus, an intact rhBARF1 was not essential for
successful penetration of the oral mucosa and entry into peripheral
blood, but the DrhBARF1 rhLCV-infected animals had a lower
level of viral load during the acute phase compared to infection
with WT rhLCV.
Oral Inoculation of rhLCV-naı ¨ve Rhesus Macaques with a
Recombinant rhLCV Encoding a Defective rhBARF1:
Persistent Infection
To determine whether DrhBARF1 rhLCV could establish
persistent infection, PBMC samples from multiple time points .16
weeks post-oral inoculation were tested by rhEBER RT-PCR. In
all three DrhBARF1 rhLCV-inoculated animals, rhEBER was
detectable in intermittent PBMC aliquots (Figure 1B). 11 of 33
PBMC aliquots tested positive (33.3%) in the persistent phase for
Mm263-05, 6 of 22 PBMC aliquots tested positive (27.3%) for
Mm78-05, and 1 of 21 positive PBMC aliquots tested positive
(4.8%) for Mm98-06. Mm98-96 was also orally rechallenged with
DrhBARF1 rhLCV at 40 weeks post-inoculation. There was an
Author Summary
Epstein-Barr virus (EBV) is a herpesvirus that persistently
infects nearly all humans by adulthood. Acute and persistent
phases of EBV infection are associated with a variety of
human diseases, including infectious mononucleosis and
cancer. To investigate how EBV interacts with the host to
successfully establish acute and persistent infection, we
combined the power of the rhesus macaque animal model
for EBV infection with genetic engineering of the EBV-related
herpesvirus, or lymphocryptovirus (LCV), that naturally infects
rhesus macaques. We created a recombinant rhLCV carrying
a mutated EBV BARF1 homologue, a replication-associated
viral protein that is secreted and blocks Colony Stimulating
Factor-1 (CSF-1) signaling, a cytokine important for innate
immunity. Oral inoculation of rhesus macaques showed that
the virus’ ability to block CSF-1 was important for achieving
the normally high viral loads during acute infection, and
surprisingly, was also needed to establish normal levels of
virus infection, or viral setpoint, during persistent infection.
These studies show that virus-mediated interruption of
innate immunity is critical for both acute and persistent
phases of EBV infection. Understanding how EBV successfully
infects humans and how the natural history of EBV infection
can be disrupted will aid in development of vaccines to
prevent EBV-associated diseases.
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during the acute (40.7%) and persistent (37.5%) periods following
re-inoculation. Overall, the rate of positive rhEBER RT-PCR
testing during the persistent phase of DrhBARF1 rhLCV infection
(4.8%–37.5%) was much lower than the nearly universal rhEBER
RT-PCR positive results during persistent infection with WT
rhLCV (93.8%–100%). Of note, the PBMC aliquots tested from
Mm141-97 and Mm144-97 contained 3–5610
6 cells (Figure 1C,
circles), whereas many of the PBMC aliquots from DrhBARF1
rhLCV-infected animals contained 10610
6 PBMC (Figure 1B,
diamonds). Thus, the rhBARF1-defective rhLCV was capable of
establishing persistent infection, but the intermittent detection,
even when using aliquots with larger numbers of cells, indicated a
lower frequency of virus-infected cells in the peripheral blood
of DrhBARF1 rhLCV-infected animals during persistent
infection.
rhLCV Encoding a Defective rhBARF1 Establishes a Lower
Virus Setpoint during Persistent Infection
To more precisely quantitate the frequency of virus-infected
cells in the peripheral blood, or virus setpoint, during persistent
rhLCV infection, limiting dilution analysis with rhEBER RT-PCR
was performed on PBMC collected from a single time point.
PBMC were aliquoted to provide multiple replicates with
decreasing numbers of cells, eg 5 replicates with 10
6 cells, 5
replicates with 0.5610
6 cells, etc. A representative experiment
using PBMC obtained from a rhesus macaque in the conventional
colony, ie naturally infected with rhLCV, is shown in Figure 2A.
All replicates with 125000, 62500, and 31250 PBMC/replicate
tested positive, whereas 4/5, 2/4, 1/5, and 0/4 tested positive
from replicates with 15600, 7800, 3900, and 1950 PBMC/
replicate respectively. By Poisson distribution and application of
extreme limiting dilution analysis (ELDA) to account for the small
Figure 1. rhEBER expression in PBMC after experimental oral inoculation of rhesus macaques with rhLCV. A) Representative southern
blot hybridization following RT-PCR amplification for rhEBER (top panel) and GAPDH (lower panel) from PBMC RNA in Mm263-05 after DrhBARF1
rhLCV inoculation. RNA from a rhLCV-infected B cell line and LCV-negative BJAB cells served as positive (P) and negative (N) controls respectively. B)
Schematic representation of positive (filled symbols) and negative (open symbols) rhEBER RT-PCR results on PBMC aliquots from three rhLCV-naı ¨ve
rhesus macaques inoculated with DrhBARF1 rhLCV (Mm263-05, Mm78-05, and Mm98-96). Aliquots containing 3 or 5610
6 PBMC are shown as circles,
and aliquots containing 10610
6 PBMC are shown as diamonds. The percentage of positive samples during the acute (weeks 1–16 post-inoculation
(pi)) and persistent (weeks .16 pi) phases of infection are shown in boxes to the right. Mm98-96 was orally re-challenged with DrhBARF1 rhLCV (2
nd)
40 weeks after the first (1
st) oral inoculation. C) Schematic representation of rhEBER RT-PCR from PBMC aliquots after oral inoculation with WT rhLCV
in 2 rhLCV-naı ¨ve rhesus macaques (Mm141-97 and Mm144-97).
doi:10.1371/journal.ppat.1003095.g001
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PBMC (with a 95% confidence interval between 5,976 and
21,143) was estimated (Figure 2B). Results from 9 random,
naturally infected rhesus macaques showed an average frequency
of 1 infected cell per 115,943 PBMC with a range of 1 in 8,
342–570,565 during persistent infection (Figure 2C; natural
infection).
To determine whether experimental infection with WT rhLCV
could establish persistent infection at levels similar to natural
infection, limiting dilution assays were performed using PBMC
from Mm141-97 and Mm144-97 obtained years after experi-
mental oral inoculation with WT rhLCV. These assays showed a
virus setpoint of 1 infected cell per 558,765 and 377,815 PBMC
respectively (Figure 2C; WT), only slightly lower than the virus
setpoints established in natural infection. Thus, experimental
rhLCV infection can reproduce virus setpoints comparable to
that seen in naturally infected animals. Differences between
experimental and natural infections, eg different viral strains,
viral titer of the oral challenge, and potential for multiple
challenge/reinfections, may contribute to the slight differences in
virus setpoints.
PBMC from DrhBARF1 rhLCV-infected animals were tested by
limiting dilutionand rhEBER RT-PCRto determinevirus setpoints
during persistent infection. Few replicates tested positive for
rhEBER expression (1/25 for Mm263-05, 2/33 for Mm98-96,
and 0/12 for Mm78-05) even though the highest numbers of
PBMC/replicate were increased to 2610
6, 1.5610
6, and 2610
6
PBMC/replicate respectively. Poisson distribution using ELDA
indicated that the frequencies of rhLCV-infected cells inMm263-05
and Mm98-96 were on the order of 1 in 24.5 million and 1 in 12.8
million PBMC respectively (Figure 2C, DrhBARF1). No reliable
estimate can be made for Mm78-05 in the absence of a positive
replicate, but the number of replicates and PBMC/replicate used
indicated the actual frequency of rhLCV-infected cells was less than
1 in 3.8 million PBMC. The precision of these analyses could
theoretically be improved by using larger numbers of PBMC/
replicate, but this could not be done given the limit of blood allowed
per single phlebotomy. The analysis indicated that the virus setpoint
during persistent infection was approximately 100 fold lower with
DrhBARF1 rhLCV (mean of 1 in 15.3 million PBMC for Mm263-
05 and Mm98-96) compared to animals with natural rhLCV
infection (mean of 1 in 115,943 PBMC).
To support the hypothesis that oral inoculation with DrhBARF1
rhLCV resulted in persistent infection at a very low frequency, we
purified CD20+ B cells from PBMC to test whether rhEBER could
be more easily detected if we increased the number of target cells
in a single sample. Affinity purification of B cells should increase
the sensitivity of detection by enriching for rhLCV-infected cells
and by eliminating dilution of rhEBER RNA by nucleic acids from
non-B cells. In Figure 3A, rhEBER RT-PCR testing was
performed with RNA isolated from BJAB cells (a LCV-negative
B lymphoma cell line), 0.9610
6 B cells from Mm141-97, and
1.8610
6 B cells from Mm263-05. rhEBER were strongly detected
in RNA from Mm141-97, an animal experimentally infected with
WT rhLCV, and not in RNA from the negative control BJAB. A
weaker, but positive, rhEBER signal was obtained using the RNA
from Mm263-05, experimentally infected with DrhBARF1
rhLCV. A similar experiment is shown in Figure 3B where
rhEBER were readily detected in RNA from 0.2610
6 B cells of a
naturally rhLCV-infected animal, not detected in RNA from
2.2610
6 B cells of a rhLCV-naı ¨ve animal, and detected in RNA
from 1610
6 B cells of Mm98-96, experimentally infected with
DrhBARF1 rhLCV. The ability to detect rhLCV infection using
larger numbers of B cells confirmed the presence of persistent
infection in DrhBARF1 rhLCV-infected animals. The results were
also consistent with both the limiting dilution studies and
intermittent rhEBER positivity in PBMC aliquots over time,
indicating a low virus setpoint after oral inoculation with
DrhBARF1 rhLCV.
Figure 2. Limiting dilution analysis using rhEBER RT-PCR to
determine frequency of rhLCV-infected cells during persistent
infection. A) rhEBER RT-PCR results of serially diluted PBMC aliquots
(cell number per aliquot indicated above blot) from a single blood draw
during persistent infection in a rhesus macaque naturally infected with
rhLCV. B) A log-fraction plot of limiting dilution analysis for rhEBER RT-
PCR data in panel A derived by extreme limiting dilution analysis [23].
The slope of the solid line is the log-active cell fraction. The 95%
confidence interval is shown by the dotted lines. C) Summary of rhLCV
virus setpoints during persistent infection in naturally infected animals
or animals experimentally infected with WT rhLCV, recombinant rhLCV
containing a mutated rhBARF1 (DrhBARF1), or recombinant rhLCV
where the rhBARF1 ORF was repaired (WTr). Geometric means are
represented by solid horizontal lines.
doi:10.1371/journal.ppat.1003095.g002
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with rhLCV Encoding a Defective rhBARF1
We asked whether the low virus setpoints in DrhBARF1
rhLCV-infected animals were associated with strong immune
responses that could drive virus setpoints lower than usual.
Surprisingly, DrhBARF1 rhLCV infection was associated with
delayed or undetectable adaptive humoral and cellular immune
responses. Serum antibody responses against the small viral capsid
antigen (rhsVCA; rhBFRF3) were undetectable from Mm98-96
and 78-05 for the entire study period, even though rhsVCA serum
antibody responses are ubiquitous in macaques with natural
rhLCV infection, as they are in EBV-infected humans [22]. In
addition, no serum antibody responses from Mm98-96 and 78-05
were detected against recombinant rhLCV lytic infection proteins
rhBRLF1, rhBZLF1, rhBMRF1, rhBILF2, rhBALF4, and
rhBALF2 even though we previously described that serum
antibody responses against these antigens can be detected in
61%, 83%, 90%, 95%, 100%, and 100% of naturally infected
animals respectively [8]. rhLCV-specific T cell responses could not
be detected from Mm78-05 at weeks 23 and 125 post-inoculation
nor from Mm98-96 at weeks 63 and 177 post-inoculation by in
vitro expansion using autologous rhLCV-immortalized B cell lines,
as previously described [6]. Thus, any rhLCV-specific adaptive
immune response to DrhBARF1 rhLCV infection in these animals
was below the level of detection by these assays and much lower
than the level of adaptive responses typically present in naturally
infected animals.
rhLCV-specific serologic responses were detected after
DrhBARF1 rhLCV inoculation in Mm263-05, but they were
delayed compared to infection with WT rhLCV. As shown in
Figure 4, serum antibodies to rhsVCA in Mm263-05 were
detected beginning at week 42, whereas rhsVCA-specific antibod-
ies are typically detected by week 7 after experimental inoculation
with WT rhLCV [10]. rhsVCA-specific antibodies in Mm263-05
rose over time and remained positive during the study through
week 142, consistent with persistent rhLCV infection. Serologic
responses were also detected against rhBMRF1 and rhBALF4 at
week 18, both responses appearing delayed compared to weeks 6
and 8 after infection with WT rhLCV [8]. Mm263-05 also
developed serologic responses to rhBILF2 at week 30, but
rhBILF2 serologic responses to WT rhLCV are variable and less
predictable [8]. rhLCV-specific T cells were not detected in
Mm263-05 at week 137 post-inoculation after stimulation with
autologous rhLCV-immortalized B cells. Thus, even though some
serologic responses were detected in Mm263-05, they were still
abnormal relative to that expected for WT rhLCV infection, they
developed after the low DrhBARF1 rhLCV setpoint had been
established, and T cell responses were not detected. These results
indicated that the low virus setpoints established during
DrhBARF1 rhLCV persistent infection were more likely due to
a defect in establishing persistent infection, as opposed to ongoing
suppression of virus setpoints by a strong immune response.
rhLCV with a Defective rhBARF1 Can Establish a Virus
Setpoint Similar to WT rhLCV in an Immunosuppressed
Host
If rhBARF1 were required for immune evasion in vivo, we
predicted that the blunted acute viral load and low virus setpoint
in persistent infection after DrhBARF1 rhLCV inoculation could
be normalized by immunosuppressing the host. A rhLCV-naı ¨ve
macaque (Mm278-98) was first immunosuppressed by Simian/
Human Immunodeficiency Virus (SHIV) infection followed by
oral inoculation with 10
6 TU of DrhBARF1 rhLCV. As shown in
Figure 5, rhEBER expression was detected in PBMC beginning at
week 2 post-inoculation and in the vast majority of PBMC aliquots
tested from the acute phase (17/20; 85%). Similarly, rhEBER
expression was detected in the vast majority of PBMC aliquots
tested from the persistent phase of infection (24/28; 85.7%). The
high frequency of PBMC aliquots testing positive for rhEBER
expression during acute and persistent phases after DrhBARF1
rhLCV inoculation of an immunosuppressed host was more
similar to experimental infection with WT rhLCV (Mm141-97
and Mm144-97) than to DrhBARF1 rhLCV infection of
immunocompetent hosts (Mm263-05, Mm98-96, and Mm78-05).
Figure 3. Detection of rhLCV infection in purified B cells during
persistent infection after oral inoculation with DrhBARF1
rhLCV. rhEBER RT-PCR using RNA from affinity purified CD20+ B cells
from DrhBARF1 rhLCV-infected animals Mm263-05 (A) and Mm98-96
(B). The number of affinity purified B cells used is shown below each
panel. Positive and negative control RNAs were derived from purified B
cells from a WT rhLCV-infected (Mm141-97) and LCV-negative BJAB in
panel A, and purified B cells from a naturally infected rhesus macaque
and rhLCV-naı ¨ve rhesus macaque in panel B.
doi:10.1371/journal.ppat.1003095.g003
Figure 4. Delayed serologic responses to rhLCV antigens after
oral inoculation with DrhBARF1 rhLCV. The presence of serum
antibodies in Mm263-05 was determined by enzyme immunoassay
against an immunodominant peptide for the rhLCV rhBFRF3 small viral
capsid antigen (rhsVCA) and purified recombinant proteins for rhBZLF1,
rhBRLF1, rhBMRF1, rhBALF2, rhBALF4, and rhBILF2. Results are
expressed as fold increase in optical density over background wells
with no serum.
doi:10.1371/journal.ppat.1003095.g004
EBV Infection and CSF-1 Immune Evasion
PLOS Pathogens | www.plospathogens.org 5 December 2012 | Volume 8 | Issue 12 | e1003095Limiting dilution analysis of Mm278-98 PBMC taken at week 159
post-inoculation showed that approximately 1 in 195,725 PBMC
were infected, a level more comparable to animals experimentally
infected with WT rhLCV (1 in 115,943; Figure 2C) than
immunocompetent animals infected with DrhBARF1 rhLCV (1 in
15.3 million; Figure 2C). These results indicated that SHIV-induced
immunosuppression can rescue the phenotype of DrhBARF1 rhLCV
infection and that DrhBARF1 rhLCV was capable of establishing
normal rhLCV setpoints under certain conditions.
rhLCV-specific adaptive immune responses were detected in
Mm278-98. Serum antibodies to the rhsVCA were detected
beginning at week 41 post-oral inoculation, and serum antibodies
to, rhBALF2 ($ week 6), rhBMRF1 ($ week25), and rhBALF4 ($
week 25), but not rhBZLF1, rhBRLF1, and rhBILF2, were
detected. CD8+ T cell responses specific for rhEBNA-2, rhEBNA-
3C, rhBRLF1, rhBLLF2, and rhBZLF1 were also detected in T
cell lines derived from PBMC drawn at weeks 77, 81, 88, 97, and
102 weeks post-oral inoculation. Thus, DrhBARF1 rhLCV could
readily induce adaptive immune responses in immunosuppressed
hosts where it achieved higher viral loads during acute infection
and higher virus setpoints during persistent infection.
Recovery of rhLCV Encoding a Defective rhBARF1 from
the Peripheral Blood after Experimental Oral Inoculation
To determine whether virus in the infected host retained the
same molecular genotype of the inoculating virus, we cultured
PBMC in vitro for spontaneous outgrowth of virus-immortalized B
cells. No spontaneously growing B cell lines could be derived from
immunocompetent animals infected with DrhBARF1 rhLCV
(Mm263-05, Mm98-96, and Mm78-05), likely due to the very
low frequency of infected cells. A spontaneously growing B cell line
was derived from PBMC collected at week 3 post-inoculation in
the immunosuppressed host (Mm278-98).
The rhLCV strain isolated from the peripheral blood of
Mm278-98 was identified by PCR amplification of rhBARF1
viral DNA from the spontaneous B cell line. DrhBARF1 rhLCV
DNA has a unique loxP scar sequence in the rhBARF1 coding
sequence where the Bacterial Artificial Chromosome (BAC) vector
sequences were initially inserted and later excised [20]. Cre-
mediated excision of the BAC vector sequences from the
recombinant virus leaves 89 nucleotides from the loxP scar
sequence in rhBARF1 resulting in a frame shift and premature
termination of the rhBARF1 coding sequence. Thus, the 89
additional nucleotides and loxP scar sequence at the rhBARF1
locus provide a unique molecular signature for DrhBARF1
rhLCV.
PCR amplification across the BAC vector insertion site
distinguishes DrhBARF1 rhLCV from WT rhLCV, as shown in
Figure 5B. A 358 bp PCR fragment could be amplified from a cell
line infected with WT rhLCV, and it hybridized with an internal,
radiolabelled rhBARF1 probe (Figure 5B, top panel, WT). PCR
amplification from DrhBARF1 rhLCV-immortalized cell lines
derived in tissue culture resulted in a slightly larger, 447 bp DNA
fragment that not only hybridized with the rhBARF1 probe
(Figure 5B, upper panel, DrhBARF1 1 & 2), but also a loxP probe
(Figure 5B, lower panel). Similarly, PCR amplification from the
spontaneous Mm278-98 B cell line (Mm278-98sp) resulted only in
the larger 447 bp PCR product and contained the loxP scar
sequence. These studies provide formal proof that the same
molecular clone used to orally inoculate Mm278-98 was capable of
penetrating the oral mucosa and infecting cells in the peripheral
blood where it could be recovered as a spontaneous B cell line in
vitro.
Repair of the rhLCV rhBARF1 Open Reading Frame
Restores Virus Setpoints in Immunocompetent Hosts
To demonstrate that the rhBARF1 mutation was responsible for
the DrhBARF1 rhLCV phenotype, the rhBARF1 ORF in the
DrhBARF1 rhLCV BAC was restored [20], and the wild type
repaired virus (WTr) was used to orally inoculate immunocom-
petent rhLCV-naı ¨ve rhesus macaques, Mm364-98 and Mm151-
97. As shown in Figure 6, rhEBER were detected at weeks 1-3
post-inoculation with positive results in 15/16 (93.8%) and 12/14
(85.7%) of aliquots containing 3–5610
6 PBMC during acute
infection. 12/14 (85.7%) and 13/15 (86.7%) PBMC aliquots were
positive during persistent infection. The kinetics of rhEBER
expression in PBMC after oral inoculation with WTr was
comparable to experimental infection with WT rhLCV
(Figure 1C; Mm141-97 and Mm144-97) from which the BAC
was originally derived.
Limiting dilution analysis showed virus setpoints of 1 in 43,317
and 1 in 1,404,968 PBMC for Mm364-98 and Mm151-97 at
weeks 19 and 29 respectively, levels comparable to both natural
rhLCV infection and experimental WT rhLCV infection
(Figure 2C). Repeat testing at weeks 24 and 32 post-inoculation
Figure 5. Experimental oral inoculation of an immunosup-
pressed, rhLCV-naı ¨ve rhesus macaque with DrhBARF1 rhLCV.
A) rhEBER RT-PCR results from PBMC of a SHIV-immunosuppressed
rhesus macaque (Mm278-98) after oral inoculation with DrhBARF1
rhLCV. B) Molecular signature for DrhBARF1 rhLCV DNA in a
spontaneously growing B cell line recovered from Mm278-98 PBMC 3
weeks after oral inoculation with DrhBARF1 rhLCV (Mm278-98sp).
rhBARF1 DNA was PCR amplified from control B cell lines containing WT
rhLCV, DrhBARF1 rhLCV, or no LCV (neg ctrl) and hybridized with either
a rhBARF1 or loxP probe to differentiate the WT rhLCV genome
signature (358 bp, rhBARF1+,l o x P 2)f r o mt h eDrhBARF1 rhLCV
signature (447 bp, rhBARF1+, loxP+). The rhLCV genome recovered in
a spontaneous B cell line from the blood after oral inoculation of
Mm278-98 has a DrhBARF1 rhLCV signature (Mm278-98sp).
doi:10.1371/journal.ppat.1003095.g005
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Mm364-98 and Mm151-97 respectively indicating that the virus
setpoint was relatively stable during persistent infection in
experimentally infected rhesus macaques and that persistent
infection was achieved by 19 weeks post-oral inoculation. Reversal
of the abnormal phenotype by repair of the rhBARF1 ORF
indicated that the loss of CSF-1 blocking ability was linked to the
lower viral load during acute infection and lower virus setpoints
during persistent infection with DrhBARF1 rhLCV.
Discussion
These experiments break new ground in two major areas by
taking studies of EBV gene function into the context of a natural
host and by exploring viral blockade of CSF-1 signaling, an
immune evasion strategy not previously described for any other
virus. Our studies indicate that viral amplification during acute
EBV infection is susceptible to CSF-1-induced immune responses
since mutating rhBARF1 resulted in blunting of acute viral load
during the first 16 weeks after oral inoculation. In addition, we
found a dramatic lowering of the virus setpoint during persistent
infection when the virus was incapable of blocking CSF-1-induced
immune responses. This anti-viral effect could be reversed by
either immunosuppressing the host via SHIV infection or by
restoring CSF-1 blocking ability to the rhBARF1 ORF.
An important role for BARF1 during acute EBV infection
might be predicted since it is expressed during lytic replication [24]
and lytic replication is assumed to be an important mechanism for
viral amplification during acute infection. However, there is little
published evidence to support this assumption. Anti-viral drugs,
such as acyclovir, that can block EBV replication have shown no
significant efficacy in clinical trials with IM patients [25,26]. One
interpretation could be that lytic replication is not important in
acute EBV infection. Another interpretation may be that anti-viral
therapy is initiated too late in IM patients to be effective, since
viral amplification through lytic replication may have already
occurred by the time patients present with symptoms and are
recruited into a clinical trial. Human epidemiologic studies
indicate that viral inoculation occurs approximately 6 weeks
before IM symptoms develop [27], and our animal studies show
that virus usually becomes detectable in the peripheral blood
within 3 weeks after oral inoculation. Similarly, the failure to find
robust viral replication in tonsillar epithelial cells of IM patients
may be due to the timing of the studies [28], as opposed to
evidence against an important role for lytic viral replication in
acute infection. Our results provide the first experimental evidence
linking lytic EBV replication to viral amplification during acute
EBV infection.
The mechanisms by which CSF-1 enhances immune control of
acute EBV infection remain to be identified. CSF-1 induces
differentiation and maturation of monocytes into active phago-
cytes in tissue culture [16], and CSF-1 administration in vivo can
increase blood monocytes and tissue resident macrophages [29].
Thus, EBV-infected cells during acute infection may be particu-
larly sensitive to CSF-1-activated phagocytic cells and tissue
macrophages. CSF-1 also acts on other components of the
immune system that may contribute to its anti-viral effect. CSF-
1 increases conventional and plasmacytoid dendritic cells that
produce interferon alpha and activate NK cells [30,31], and CSF-
1 has been reported to mobilize and enhance NK cytolytic activity
[32]. Thus, it is tempting to speculate that BARF1 may have been
acquired as a unique EBV strategy to evade NK cells. There are
multiple lines of evidence linking EBV susceptibility to NK cells.
Patients with X-Linked Lymphoproliferative Syndrome (XLP)
suffer from fatal IM or lymphomas upon primary EBV infection,
but do not have unusual susceptibility to other microbial
pathogens [33]. In XLP, mutations in the signaling lymphocytic
activation molecule (SLAM)-associated protein (SAP) prevent
activation of NK cell cytotoxicity against EBV-infected B cells
[34]. Severe combined immunodeficiency (SCID) mice engrafted
with human PBMC depleted of NK cells are more susceptible to
fatal lymphoproliferation of infused EBV-infected B cells than
non-depleted controls, indicating a role for NK cells in preventing
outgrowth of infected B cells [35]. B cell immortalization by EBV
infection in tissue culture is also sensitive to NK cells [36], and in
particular to tonsil-derived NK cells that may be most proximal to
early viral events during acute EBV infection in humans [37].
Interestingly, HIV and SHIV infection have been associated with
decreases in circulating NK cells and NK cell function [38,39],
and this may explain why SHIV-induced immunosuppression was
associated with rescue of a normal viral phenotype after
DrhBARF1 rhLCV inoculation.
The markedly decreased virus setpoint during persistent infection
with DrhBARF1 rhLCV was surprising. Viral set points during
persistent EBV infection are believed to be independent of lytic viral
replication since they remain largely unchanged in patients on
chronic acyclovir therapy [2], although recent data has challenged
this paradigm [40]. A potential model to explain our findings with
DrhBARF1 rhLCV may be that the virus setpoint during persistent
infection is determined in part by the level of viral load during acute
infection, ie the effect on virus setpoint in persistent infection is a
consequence of, or dependent upon, the rhBARF1 effect in acute
infection. This is similar to Herpes Simplex Virus where multiple
factors during acute infection, including viral replication, multiplicity
of infection, and location of replication, can contribute to the level of
persistent, latent infection established in neurons [41]. Alternatively,
rhBARF1 may have an additional and independent effect on
Figure 6. Experimental infection with a recombinant rhLCV
clone where the rhBARF1 ORF in DrhBARF1 rhLCV was
repaired. Schematic representation of rhEBER RT-PCR results from
PBMC aliquots during acute and persistent phases of infection after oral
inoculation of 2 rhLCV-naı ¨ve rhesus macaques (Mm364-98 and Mm151-
97) with the recombinant rhLCV containing a repaired rhBARF1 ORF
(WTr).
doi:10.1371/journal.ppat.1003095.g006
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lytic replication [24], BARF1 mRNA can be detected in nasopha-
ryngealcarcinoma cells[42,43] and EBV-immortalizedB cells[44] in
the absence of lytic replication opening up the theoretic possibility
that BARF1 may be promiscuously expressed during persistent
infection in latently infected peripheral blood B cells. Further studies
will be required to understand the mechanistic basis for the low virus
setpoints established by DrhBARF1 rhLCV, but this is the first
experimental demonstration that the natural history of persistent
LCV infection can be attenuated.
The failure to generate robust adaptive immune responses in
hosts persistently infected with DrhBARF1 rhLCV was also
surprising since control of latently EBV-infected B cells in humans
is tightly linked to adaptive, and in particular, T cell immune
responses [1]. This indicated that adaptive immune responses were
not the principle driver for the low virus setpoint during persistent
DrhBARF1 rhLCV infection. It may be more likely that
DrhBARF1 rhLCV is a conditionally attenuated virus, ie in a
healthy, immunocompetent host, it is incapable of establishing a
normal virus setpoint in the face of intact CSF-1-induced immune
responses, and the lower virus setpoint provides insufficient
antigen expression to stimulate robust adaptive immune responses.
When hosts are immunosuppressed or CSF-1 is blocked, the virus
can achieve higher setpoints associated with more antigenic
stimulation and easily detectable adaptive immune responses. This
unusual state of persistent infection with very low virus setpoints
and difficult to detect adaptive immune responses may need to be
considered when evaluating vaccine studies, ie to differentiate
sterilizing immunity from an altered natural history of persistent
EBV infection with a very low virus setpoint.
Altering the natural history of persistent EBV infection is likely to
be an important component for an effective EBV vaccine for IM
and for EBV-associated malignancies. Blunting the acute viral load,
either in terms of kinetics or absolute magnitude, may be an
important strategy for preventing the excessive immune activation
that causesIM.PhaseIIclinicaltestinginhumanshasdemonstrated
proof-of-principle that a gp350 subunit vaccine can prevent IM, but
the mechanism by which the vaccine prevents disease remains
unclear [45]. Gp350 is the major membrane glycoprotein on the
virus and a major target for serum neutralizing antibodies [46].
Serum neutralizing antibodies may protect from IM by providing
sterilizing immunity or by altering the speed or magnitude of viral
amplification during acute EBV infection. Our studies provide
evidence that targeting lytic replication can blunt viral amplification
during acute infection and that lytic EBV replication may be
especially susceptible to CSF-1-mediated immune responses.
F o ra ne f f e c t i v eE B Vc a n c e rv a c c i n e ,l o w e rv i r u ss e t p o i n t sm a y
translate into a decreased number of EBV-infected cells at risk for
malignant transformation and a stochastic reduction in the develop-
ment of EBV-associated malignancies over time. If the virus setpoint
during persistent infection is linked to viral load during acute
infection, then an EBV vaccine targeting lytic replication and
reducing viralamplification in acute infection may be effective against
both IM and EBV-associated cancers. Our studies indicate that
tipping the balance in favor of host immunity against acute viral
replication can alter the natural history of both acute and persistent
phases of LCV infection, providing a potential vaccine strategy for
protection against a spectrum of EBV-associated diseases.
Materials and Methods
Ethics Statement
Animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee for Harvard
Medical School. Animals were cared for in compliance with
National Institutes of Health, US Department of Agriculture, and
Harvard Medical School guidelines for animal research. Animal
well-being was monitored multiple times throughout the day by
animal care staff, veterinary technicians, and veterinarians, and
appropriate veterinary care was provided as needed. Sedation and
analgesia were administered as indicated to minimize stress and
pain associated with any veterinary procedures.
Viruses
rhLCV-infected cell lines were grown in RPMI 1640 supple-
mented with 10% fetal bovine serum at 37uC and 5% CO2. Virus
stocks were derived from cell-free supernatants, and transforma-
tion titers were assayed [20]. The rhLCV strain LCL8664 [47]
from which the rhLCV BAC was derived, is referred to as WT
rhLCV and was obtained from the American Type Culture
Collection. DrhBARF1 rhLCV refers to the recombinant, BAC-
derived virus that has a mutated rhBARF1 open reading frame
with the carboxy terminal 70 AA truncated by insertion of a
premature stop codon after amino acid 150 (clone 16 rhLCV
[20]). WTr rhLCV is the recombinant, BAC-derived virus with a
repaired rhBARF1 open reading frame [20].
Animal Infections
rhLCV-naı ¨ve rhesus macaques were obtained from an extended
specific pathogen-free (spf) colony at the New England Primate
Research Center (NEPRC). This self-sustaining breeding colony
undergoes regular serologic screening to ensure that animals are
free of infection from several simian viruses including herpes B,
rhesus cytomegalovirus, rhesus rhadinovirus, and rhLCV. The
NEPRC extended spf colony has been free of rhLCV infection for
over a decade. Animals were inoculated with 10
6 transforming
units (TU) of cell-free virus applied non-traumatically throughout
the oral cavity. Infection with Simian/Human Immunodeficiency
Virus (SHIV) was as described [10].
Serologic Assays
Serum antibodies against the rhLCV small viral capsid antigen
(rhBFRF3) were detected by peptide immunoassays [22]. Serum
antibodies against rhBZLF1, rhBRLF1, rhBMRF1, rhBALF2,
rhBALF4, or rhBILF2 protein were detected by enzyme immu-
noassays using recombinant viral antigens [8].
Real-time RT-PCR for rhLCV Encoded RNAs (rhEBER) and
Southern Blot Analysis
Total RNA was extracted using RNA-Bee reagent (Tel-Test
Inc.) on peripheral blood mononuclear cells (PBMC) or B cells
affinity purified with CD20 antibody (clone 2H7, Biolegend) and
CELLection Pan Mouse IgG kit (Invitrogen). Extracted RNA was
reverse-transcribed using Super Script II reverse transcriptase
(Invitrogen) and rhEBER173R (aaaacaggcggaccaccag) and
GAPDH-R1 (gttcacacccatgacgaacatgg) primers. Real-time PCR
was performed using SYBR green (Applied Biosystem). 18 ul or
0.02 ul of cDNA were amplified for 40 cycles (15 seconds at 95uC,
30 seconds at 60uC, and 30 seconds at 72uC) for rhEBER
(rhEBER32F; ggaggagatgagtgtgacttaaatca and rhEBER148R;
tgaaccgaagagagcagaaacc) or GAPDH (GAPDH-F; gcgagatccctc-
caaaatca and GAPDH-R2; ccagtggactccacgacgta), respectively.
Plasmids containing rhEBER (6652–7137 nt) or GAPDH (113–
510 nt, gi83641890) DNA were quantified by spectrophotometry
and diluted from 10
6 to 10
1 copies for use as standards. PCR
products were detected by gel electrophoresis, southern blot
transfer, and hybridization with a
32P end-labeled rhEBER116R
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oligonucleotide probe.
Limiting Dilution Assay for Measuring Frequency of
rhLCV-infected Cells in PBMC
PBMC were isolated by Ficoll-Hypaque density centrifugation
and cell numbers were determined using Count Bright absolute
counting beads (Invitrogen) in flow cytometry. PBMC were 2-fold
serially diluted, typically at starting concentrations of 1 or 2610
6,
and 3–5 replicates were prepared at each cell concentration.
rhEBER RT-PCR was performed using the Super Script III one-
step RT-PCR system (Invitrogen), rhEBER32 and rhEBER148R
primers, and amplification for 35 cycles (15 seconds at 95uC,
30 seconds at 60uC, and 30 seconds at 68uC). PCR products were
detected by gel electrophoresis, southern blot transfer, and
hybridization with a
32P end-labeled rhEBER116R oligonucleo-
tide probe. The frequency of rhLCV-infected cells in PBMC was
calculated from the results of limiting dilution replicate testing
using the method described by Hu, et. al. (Extreme Limiting
Dilution Analysis; http://bioinf.wehi.edu.au/software/elda/)
[23]. In all analyses, the single-hit hypothesis was not rejected.
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